XML 46 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Award Timing Disclosure
 12 Months Ended
Dec. 31, 2024
May 13, 2024
USD ($)
share
$ / shares
Jan. 04, 2024
USD ($)
share
$ / shares
Award Timing Disclosures [Line Items]      
Award Timing MNPI Disclosure
We do not have any program, plan, or obligation that requires us to grant equity awards on specified dates, although the Company’s long-standing practice has been to make annual equity grants in January and May of each year at the regularly scheduled meetings of our Compensation Committee and Board. We believe this allows management, the Compensation Committee and the Board to conduct a fulsome review of all elements of compensation on a consistent basis each year. The Board, with respect to our CEO, and the Compensation Committee, with respect to our remaining NEOs, may also grant equity awards from time to time in recognition of a NEO’s expanded duties and responsibilities or continuing contributions to the Company’s performance.
Neither the Compensation Committee nor the Board takes material nonpublic information into account when determining the timing and terms of grants of equity compensation. Further, we do not have any program, plan or practice to time grant dates of equity compensation awards in coordination with the release of material nonpublic information and have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.
Pursuant to Item 402(x) of Regulation S-K under the Exchange Act, we are providing the following information regarding awards granted to named executive officers of the Company on the following dates:
•January 4, 2024, which was one business day before the filing of a Current Report on Form 8-K with which the Company furnished a slide presentation to be used by management at the 42nd Annual J.P. Morgan Healthcare Conference; and
•May 13, 2024, which was the date of the filing of a Current Report on Form 8-K in which the Company reported the results of the 2024 Annual Meeting.
Grant dateNumber of
securities
underlying
the award		Per share exercise
price of the
award
($)		Grant date
fair value of
the award
($)		Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information
(%)
William H. Lewis01/04/2024186,97029.133,309,762 2.75 
05/13/2024209,32025.833,308,972 (2.00)
Sara Bonstein01/04/202463,56029.131,125,145 2.75 
05/13/202471,16025.831,124,912 (2.00)
Roger Adsett01/04/202463,56029.131,125,145 2.75 
05/13/202471,16025.831,124,912 (2.00)
Martina Flammer, M.D.01/04/202463,56029.131,125,145 2.75 
05/13/202471,16025.831,124,912 (2.00)
Drayton Wise01/04/202463,56029.131,125,145 2.75 
05/13/202471,16025.831,124,912 (2.00)
    
Award Timing Method Neither the Compensation Committee nor the Board takes material nonpublic information into account when determining the timing and terms of grants of equity compensation. Further, we do not have any program, plan or practice to time grant dates of equity compensation awards in coordination with the release of material nonpublic information and have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.    
Award Timing Predetermined true    
Award Timing MNPI Considered true    
Award Timing, How MNPI Considered
We do not have any program, plan, or obligation that requires us to grant equity awards on specified dates, although the Company’s long-standing practice has been to make annual equity grants in January and May of each year at the regularly scheduled meetings of our Compensation Committee and Board. We believe this allows management, the Compensation Committee and the Board to conduct a fulsome review of all elements of compensation on a consistent basis each year. The Board, with respect to our CEO, and the Compensation Committee, with respect to our remaining NEOs, may also grant equity awards from time to time in recognition of a NEO’s expanded duties and responsibilities or continuing contributions to the Company’s performance.
Neither the Compensation Committee nor the Board takes material nonpublic information into account when determining the timing and terms of grants of equity compensation. Further, we do not have any program, plan or practice to time grant dates of equity compensation awards in coordination with the release of material nonpublic information and have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. 		   
MNPI Disclosure Timed for Compensation Value false    
Awards Close in Time to MNPI Disclosures, Table
Grant dateNumber of
securities
underlying
the award		Per share exercise
price of the
award
($)		Grant date
fair value of
the award
($)		Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information
(%)
William H. Lewis01/04/2024186,97029.133,309,762 2.75 
05/13/2024209,32025.833,308,972 (2.00)
Sara Bonstein01/04/202463,56029.131,125,145 2.75 
05/13/202471,16025.831,124,912 (2.00)
Roger Adsett01/04/202463,56029.131,125,145 2.75 
05/13/202471,16025.831,124,912 (2.00)
Martina Flammer, M.D.01/04/202463,56029.131,125,145 2.75 
05/13/202471,16025.831,124,912 (2.00)
Drayton Wise01/04/202463,56029.131,125,145 2.75 
05/13/202471,16025.831,124,912 (2.00)
    
William H. Lewis [Member]      
Awards Close in Time to MNPI Disclosures      
Name   William H. Lewis William H. Lewis
Underlying Securities | share   209,320 186,970
Exercise Price | $ / shares   $ 25.83 $ 29.13
Fair Value as of Grant Date | $   $ 3,308,972 $ 3,309,762
Underlying Security Market Price Change   (0.0200) 0.0275
Sara Bonstein [Member]      
Awards Close in Time to MNPI Disclosures      
Name   Sara Bonstein Sara Bonstein
Underlying Securities | share   71,160 63,560
Exercise Price | $ / shares   $ 25.83 $ 29.13
Fair Value as of Grant Date | $   $ 1,124,912 $ 1,125,145
Underlying Security Market Price Change   (0.0200) 0.0275
Roger Adsett [Member]      
Awards Close in Time to MNPI Disclosures      
Name   oger Adsett oger Adsett
Underlying Securities | share   71,160 63,560
Exercise Price | $ / shares   $ 25.83 $ 29.13
Fair Value as of Grant Date | $   $ 1,124,912 $ 1,125,145
Underlying Security Market Price Change   (0.0200) 0.0275
Martina Flammer, M.D. [Member]      
Awards Close in Time to MNPI Disclosures      
Name   Martina Flammer, M.D. Martina Flammer, M.D.
Underlying Securities | share   71,160 63,560
Exercise Price | $ / shares   $ 25.83 $ 29.13
Fair Value as of Grant Date | $   $ 1,124,912 $ 1,125,145
Underlying Security Market Price Change   (0.0200) 0.0275
Drayton Wise [Member]      
Awards Close in Time to MNPI Disclosures      
Name   Drayton Wise Drayton Wise
Underlying Securities | share   71,160 63,560
Exercise Price | $ / shares   $ 25.83 $ 29.13
Fair Value as of Grant Date | $   $ 1,124,912 $ 1,125,145
Underlying Security Market Price Change   (0.0200) 0.0275